AstraZeneca’s Q2 earnings soar with a 5% revenue jump and 2.51B net profit, fueled by blockbuster cancer drugs—plus promising early data on their obesity drug elecoglipron, which could shake up the weight-loss market. Despite a recent trial stumble, CEO remains upbeat, targeting an 80B revenue goal by 2030.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
